Y040-7904
Based on 1 Customer Validation
Y040-7904 is a mitophagy activator. Y040-7904 enhances mitophagy by promoting mitochondria transport to autophagosomes and the fusion of autophagosomes with autolysosomes. Y040-7904 induces mitophagy through the SIRT1/FoxO3 pathway. Y040-7904 upregulates the levels of Parkin, PINK1, and LC3II/I. Y040-7904 reduces amyloid-β (Aβ) accumulation in both in vitro and in vivo models of Alzheimer’s disease.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.36%
- CAS 番号: 889662-19-5
- 分子式: C20H18O7
- 分子量:370.35
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mitochondria-Targeted Compound Library
HY-L089
-
Mitochondrial Protection Compound Library
HY-L144
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
生物活性
Y040-7904 (20 μM, 24 h) induces a detectable increase in mitolysosomes and increases the proportions of mitophagosomes (9%) and mitolysosomes (18%), higher than those induced by the two established mitophagy inducers, Urolithin A (HY-100599) and UMI-77 (HY-18628), in HT22 cells[1].
Y040-7904 (5-20 μM, 24 h) facilitates the expression of mitophagy-related proteins PINK1 and Parkin through the SIRT1-FoxO3a pathway, ultimately resulting in an elevation in mitophagy levels in HT22 cells and N2a/APPswe cells[1].
Y040-7904 (5-20 μM, 24 h) enhances mitochondrial biogenesis by upregulateing the expression of MFN2, TIM23, and TOM20 in HT22 cells[1].
Y040-7904 (5-20 μM, 24 h) mitigates APP and Aβ1-42 accumulation in N2a/APPswe cells[1].
Y040-7904 (5-20 μM, 24 h) upregulates the levels of Parkin, PINK1, and LC3II/I in N2a/APPswe cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HT22 cells, PINK1 silenced HT22 cells
-
Concentration:5, 10, and 20 μM
-
Incubation Time:24 h
-
Result:Increased the levels of mitophagy-related proteins, including PINK1, Parkin, phosphorylated Ser65-ubiquitin (pUb), and LC3B-II/LC3B–I in a dose- and time-dependent manner in HT22 cells.
Abolished the increase in mitophagy-related proteins, such as pUb and LC3 in PINK1 silenced HT22 cells.
Increased nuclear FoxO3a levels, accompanied by a concomitant decrease in cytoplasmic FoxO3a levels in HT22 cells.
Increased levels of mitochondrial marker MFN2, TIM23, and TOM20 in HT22 cells.
-
Cell Line:Neuron-2a cells (N2a/APPswe cells)
-
Concentration:5, 10, and 20 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the levels of APP and its C-terminal fragment C99 decreased intracellular Aβ1-42 levels in a dose-dependent manner in N2a/APPswe cells.
Significantly upregulated the levels of f Parkin, PINK1, and LC3II/I in N2a/APPswe cells.
-
Cell Line:HT22 cells
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Significantly promoted the nuclear localization of FoxO3a.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Transgenic C. elegans strains CL417647 and CL2006[1].
-
Dosage:500, 1000 μM
-
Administration:96 h
-
Result:Resulted in a dose-dependent reduction in Aβ1-42 levels in CL4176 worms.
Decreased the paralysis rate of CL4176 worms (76.2%, 1000 μM), compared to 89.5% in untreated worm at 30 h post temperature upshift.
Reduced paralysis rate of CL2006 worms by 29.3% compared to untreated controls.
化学情報
-
CAS 番号 889662-19-5
-
性状 Solid
-
分子量 370.35
-
分子式 C20H18O7
-
Color White to off-white
-
SMILES
O=C1C=C(C2=CC=CC=C2)C3=CC=C(O[C@H]4[C@@H]([C@H]([C@@H](CO4)O)O)O)C=C3O1
-
別名
7-(β-D-Galactopyranosyloxy)-4-phenylchromen-2-one
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
DMSO : 100 mg/mL (270.01 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (13.50 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (13.50 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7001 mL | 13.5007 mL | 27.0015 mL | 67.5037 mL |
| 5 mM | 0.5400 mL | 2.7001 mL | 5.4003 mL | 13.5007 mL | |
| 10 mM | 0.2700 mL | 1.3501 mL | 2.7001 mL | 6.7504 mL | |
| 15 mM | 0.1800 mL | 0.9000 mL | 1.8001 mL | 4.5002 mL | |
| 20 mM | 0.1350 mL | 0.6750 mL | 1.3501 mL | 3.3752 mL | |
| 25 mM | 0.1080 mL | 0.5400 mL | 1.0801 mL | 2.7001 mL | |
| 30 mM | 0.0900 mL | 0.4500 mL | 0.9000 mL | 2.2501 mL | |
| 40 mM | 0.0675 mL | 0.3375 mL | 0.6750 mL | 1.6876 mL | |
| 50 mM | 0.0540 mL | 0.2700 mL | 0.5400 mL | 1.3501 mL | |
| 60 mM | 0.0450 mL | 0.2250 mL | 0.4500 mL | 1.1251 mL | |
| 80 mM | 0.0338 mL | 0.1688 mL | 0.3375 mL | 0.8438 mL | |
| 100 mM | 0.0270 mL | 0.1350 mL | 0.2700 mL | 0.6750 mL |
Y040-7904 関連分類
HY-174806 関連分類
Powered by Bioz